CYP2D6 polymorphism is related to absent (poor metabolizers, PMs) and normal/decreased (extensive metabolizers, including ultrarapid metabolizers) metabolism of clinically important drugs. Moreover CYP2D6 is also involved in the metabolism of endogenous substrates in the brain which appear highly ...
CYP2D6 metabolizes more than 25% of current commonly used drugs including antidepressants, antipsychotics, analgesics, beta-adrenergic blocking agents, antiarrythmics, and antiemetics. The CYP2D6 gene is highly polymorphic in humans, resulting in phenotypes that vary from poor metabolizer to super ...
CYP2D6 metabolizes more than 25% of current commonly used drugs including antidepressants, antipsychotics, analgesics, beta-adrenergic blocking agents, antiarrythmics, and antiemetics. The CYP2D6 gene is highly polymorphic in humans, resulting in phenotypes that vary from poor metaboliz...
Some individuals with the poor metabolizer phenotype have no functional protein since they carry 2 null alleles whereas in other individuals the gene is absent. This gene can vary in Cell Pathway/ Category Drug metabolism, Protein Expression Brain,Liver,PCR rescued clones, Subcellular Localization ...
A relative risk of 2.626 and 5.333 for 2D6*4 and 2D6*6, respectively, and of 7.08 for poor metabolizer phenotype suggested a significant association between the hereditary susceptibility for a particular type of drug metabolism (defect alleles) and side effects. These preliminary r e s u l ...
Additionally, CYP2D6 is involved in the metabolism of endogenous substrates in the brain, and reported to be located in regions such as the cortex, hippocampus and cerebellum, which are impaired in schizophrenia. Moreover, recently we have found that CYP2D6 poor metabolizers are under-represented...
analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. Some individuals wit...
Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. CYP2D6 is polymorphically distributed so that in poor metabolizers enzyme activity is missing. The goal of this study was to compare the pharmacokinetics a... Y Caraco,J Sheller,A.J. Wood...
These polymorphisms result in various enzymatic profiles grouped into four phenotypes: poor (PM), intermediate (IM), rapid (NM) or ultrarapid (UM) metabolizers, which are correlated with variations in plasma concentrations of substrate drugs. In this study, our main hypothesis is that patients ...
Some CYP enzymes (e.g., CYP2D6, CYP1A2, CYP2C9, and CYP2C19) have common functional genetic polymorphisms that result in different phenotypes9,10,11,12,13,14. CYP2D6 is associated with several phenotypes, ranging from poor metabolizers (PMs; 5–10% in Caucasians) to ultra-rapid ...